Tranilast enhances the effect of anticancer agents in osteosarcoma

Nakashima,Takayuki; Nagano,Satoshi; Setoguchi,Takao; Sasaki,Hiromi; Saitoh,Yoshinobu; Maeda,Shingo; Komiya,Setsuro; Taniguchi,Noboru

doi:10.3892/or.2019.7150

Tranilast enhances the effect of anticancer agents in osteosarcoma

Authors:
- Takayuki Nakashima
- Satoshi Nagano
- Takao Setoguchi
- Hiromi Sasaki
- Yoshinobu Saitoh
- Shingo Maeda
- Setsuro Komiya
- Noboru Taniguchi
View Affiliations

Affiliations: Department of Orthopaedic Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890‑8520, Japan, Department of Medical Joint Materials, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890‑8520, Japan
Published online on: May 6, 2019 https://doi.org/10.3892/or.2019.7150
Pages: 176-188
Copyright: © Nakashima et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tranilast [N‑(3',4'‑dimethoxycinnamoyl)‑anthranilic acid], initially developed as an antiallergic drug, also exhibits a growth inhibitory effect on various types of cancer. Osteosarcoma is treated mainly with high‑dose methotrexate, doxorubicin, cisplatin and ifosfamide; however, 20‑30% of patients cannot be cured of metastatic disease. We investigated whether tranilast enhances the anticancer effects of chemotherapeutic drugs and analyzed its mechanism of action in osteosarcomas. Tranilast inhibited proliferation of HOS, 143B, U2OS and MG‑63 osteosarcoma cells in a dose‑dependent manner, as well as enhancing the effects of cisplatin and doxorubicin. The average combination index at effect levels for tranilast in combination with cisplatin was 0.57 in HOS, 0.4 in 143B, 0.39 in U2OS and 0.51 in MG‑63 cells. Tranilast and cisplatin synergistically inhibited the viability of osteosarcoma cells. In flow cytometric analysis, although tranilast alone did not induce significant apoptosis, the combination of tranilast and cisplatin induced early and late apoptotic cell death. Expression of cleaved caspase‑3, cleaved poly(ADP‑ribose) polymerase and p‑H2AX was enhanced by tranilast in combination with cisplatin. Tranilast alone increased expression of p21 and Bim protein in a dose‑dependent manner. Cell cycle analysis using flow cytometry demonstrated that the combination of tranilast and cisplatin increased the number of cells in the G2/M phase. Compared with cisplatin alone, the combination increased levels of phospho‑cyclin‑dependent kinase 1 (Y15). In the 143B xenograft model, tumor growth was significantly inhibited by combined tranilast and cisplatin compared with the controls, whereas cisplatin alone did not significantly inhibit tumor growth. In conclusion, tranilast has a cytostatic effect on osteosarcoma cells and enhances the effect of anticancer drugs, especially cisplatin. Enhanced sensitivity to cisplatin was mediated by increased apoptosis through G2/M arrest. Since tranilast has been clinically approved and has few adverse effects, clinical trials of osteosarcoma chemotherapy in combination with tranilast are expected.

View Figures

View References

1	Darakhshan S and Pour AB: Tranilast: A review of its therapeutic applications. Pharmacol Res. 91:15–28. 2015. View Article : Google Scholar : PubMed/NCBI
2	Ward MR, Sasahara T, Agrotis A, Dilley RJ, Jennings GL and Bobik A: Inhibitory effects of tranilast on expression of transforming growth factor-beta isoforms and receptors in injured arteries. Atherosclerosis. 137:267–275. 1998. View Article : Google Scholar : PubMed/NCBI
3	Phan TV, Ke K, Sul OJ, Park YK, Kim KK, Cho YS, Chung HT and Choi HS: Protection against ovariectomy-induced bone loss by tranilast. PLoS One. 9:e955852014. View Article : Google Scholar : PubMed/NCBI
4	Holmes DR Jr, Savage M, LaBlanche JM, Grip L, Serruys PW, Fitzgerald P, Fischman D, Goldberg S, Brinker JA, Zeiher AM, et al: Results of prevention of REStenosis with tranilast and its outcomes (PRESTO) trial. Circulation. 106:1243–1250. 2002. View Article : Google Scholar : PubMed/NCBI
5	Huang Y, Jiang H, Chen Y, Wang X, Yang Y, Tao J, Deng X, Liang G, Zhang H, Jiang W and Zhou R: Tranilast directly targets NLRP3 to treat inflammasome-driven diseases. EMBO Mol Med. 10:e86892018. View Article : Google Scholar : PubMed/NCBI
6	Tokuyama H, Kelly DJ, Cox A, Zhang Y, Thai K, Nikolic-Paterson DJ and Gilbert RE: Tranilast ameliorates experimental mesangial proliferative glomerulonephritis. Nephron Exp Nephrol. 109:e1–e7. 2008. View Article : Google Scholar : PubMed/NCBI
7	Darakhshan S, Bidmeshkipour A, Mansouri K, Saeid HM and Ghanbari A: The effects of tamoxifen in combination with tranilast on CXCL12-CXCR4 axis and invasion in breast cancer cell lines. Iran J Pharm Res. 13:683–693. 2014.PubMed/NCBI
8	Subramaniam V, Ace O, Prud'homme GJ and Jothy S: Tranilast treatment decreases cell growth, migration and inhibits colony formation of human breast cancer cells. Exp Mol Pathol. 90:116–122. 2011. View Article : Google Scholar : PubMed/NCBI
9	Izumi K, Mizokami A, Li YQ, Narimoto K, Sugimoto K, Kadono Y, Kitagawa Y, Konaka H, Koh E, Keller ET and Namiki M: Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes. Prostate. 69:1222–1234. 2009. View Article : Google Scholar : PubMed/NCBI
10	Kaneda M, Obara H, Suzuki K, Takeuchi O, Takizawa A, Osaku M, Matsubara H and Kitagawa Y: Evaluation of suppressive effects of tranilast on the invasion/metastasis mechanism in a murine pancreatic cancer cell line. Pancreas. 46:567–574. 2017. View Article : Google Scholar : PubMed/NCBI
11	Yatsunami J, Aoki S, Fukuno Y, Kikuchi Y, Kawashima M and Hayashi SI: Antiangiogenic and antitumor effects of tranilast on mouse lung carcinoma cells. Int J Oncol. 17:1151–1156. 2000.PubMed/NCBI
12	Yashiro M, Murahashi K, Matsuoka T, Nakazawa K, Tanaka H, Osaka H, Koyama T, Ohira M and Chung KH: Tranilast (N-3,4-dimethoxycinamoyl anthranilic acid): A novel inhibitor of invasion-stimulating interaction between gastric cancer cells and orthotopic fibroblasts. Anticancer Res. 23:3899–3904. 2003.PubMed/NCBI
13	Meazza C and Scanagatta P: Metastatic osteosarcoma: A challenging multidisciplinary treatment. Expert Rev Anticancer Ther. 16:543–556. 2016. View Article : Google Scholar : PubMed/NCBI
14	Chandar N, Billig B, McMaster J and Novak J: Inactivation of p53 gene in human and murine osteosarcoma cells. Br J Cancer. 65:208–214. 1992. View Article : Google Scholar : PubMed/NCBI
15	Ganjavi H, Gee M, Narendran A, Parkinson N, Krishnamoorthy M, Freedman MH and Malkin D: Adenovirus-mediated p53 gene therapy in osteosarcoma cell lines: Sensitization to cisplatin and doxorubicin. Cancer Gene Ther. 13:415–419. 2006. View Article : Google Scholar : PubMed/NCBI
16	Allan LA and Fried M: p53-dependent apoptosis or growth arrest induced by different forms of radiation in U2OS cells: p21WAF1/CIP1 repression in UV induced apoptosis. Oncogene. 18:5403–5412. 1999. View Article : Google Scholar : PubMed/NCBI
17	Nakamura S, Nagano S, Nagao H, Ishidou Y, Yokouchi M, Abematsu M, Yamamoto T, Komiya S and Setoguchi T: Arsenic trioxide prevents osteosarcoma growth by inhibition of GLI transcription via DNA damage accumulation. PLoS One. 8:e694662013. View Article : Google Scholar : PubMed/NCBI
18	Takahashi K, Setoguchi T, Tsuru A, Saitoh Y, Nagano S, Ishidou Y, Maeda S, Furukawa T and Komiya S: Inhibition of casein kinase 2 prevents growth of human osteosarcoma. Oncol Rep. 37:1141–1147. 2017. View Article : Google Scholar : PubMed/NCBI
19	Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55. 1984. View Article : Google Scholar : PubMed/NCBI
20	Isaji M, Miyata H, Ajisawa Y, Takehana Y and Yoshimura N: Tranilast inhibits the proliferation, chemotaxis and tube formation of human microvascular endothelial cells in vitro and angiogenesis in vivo. Br J Pharmacol. 122:1061–1066. 1997. View Article : Google Scholar : PubMed/NCBI
21	Suzawa H, Kikuchi S, Arai N and Koda A: The mechanism involved in the inhibitory action of tranilast on collagen biosynthesis of keloid fibroblasts. Jpn J Pharmacol. 60:91–96. 1992. View Article : Google Scholar : PubMed/NCBI
22	Subramaniam V, Chakrabarti R, Prud'homme GJ and Jothy S: Tranilast inhibits cell proliferation and migration and promotes apoptosis in murine breast cancer. Anticancer Drugs. 21:351–361. 2010. View Article : Google Scholar : PubMed/NCBI
23	Shapiro GI and Harper JW: Anticancer drug targets: Cell cycle and checkpoint control. J Clin Invest. 104:1645–1653. 1999. View Article : Google Scholar : PubMed/NCBI
24	Siddik ZH: Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene. 22:7265–7279. 2003. View Article : Google Scholar : PubMed/NCBI
25	Goto A, Kanda H, Ishikawa Y, Matsumoto S, Kawaguchi N, Machinami R, Kato Y and Kitagawa T: Association of loss of heterozygosity at the p53 locus with chemoresistance in osteosarcomas. Jpn J Cancer Res. 89:539–547. 1998. View Article : Google Scholar : PubMed/NCBI
26	Jaffe N: Historical perspective on the introduction and use of chemotherapy for the treatment of osteosarcoma. Adv Exp Med Biol. 804:1–30. 2014. View Article : Google Scholar : PubMed/NCBI
27	Sabisz M and Skladanowski A: Modulation of cellular response to anticancer treatment by caffeine: Inhibition of cell cycle checkpoints, DNA repair and more. Curr Pharm Biotechnol. 9:325–336. 2008. View Article : Google Scholar : PubMed/NCBI
28	Hu Y, Li C, Li H, Li M and Shu X: Resveratrol-mediated reversal of tumor multi-drug resistance. Curr Drug Metab. 15:703–710. 2014. View Article : Google Scholar : PubMed/NCBI
29	Rogosnitzky M, Danks R and Kardash E: Therapeutic potential of tranilast, an anti-allergy drug, in proliferative disorders. Anticancer Res. 32:2471–2478. 2012.PubMed/NCBI
30	Murahashi K, Yashiro M, Inoue T, Nishimura S, Matsuoka T, Sawada T, Sowa M and Hirakawa-Ys Chung K: Tranilast and cisplatin as an experimental combination therapy for scirrhous gastric cancer. Int J Oncol. 13:1235–1240. 1998.PubMed/NCBI
31	Mitsuno M, Kitajima Y, Ohtaka K, Kai K, Hashiguchi K, Nakamura J, Hiraki M, Noshiro H and Miyazaki K: Tranilast strongly sensitizes pancreatic cancer cells to gemcitabine via decreasing protein expression of ribonucleotide reductase 1. Int J Oncol. 36:341–349. 2010.PubMed/NCBI
32	Darakhshan S, Bidmeshkipour A, Khazaei M, Rabzia A and Ghanbari A: Synergistic effects of tamoxifen and tranilast on VEGF and MMP-9 regulation in cultured human breast cancer cells. Asian Pac J Cancer Prev. 14:6869–6874. 2013. View Article : Google Scholar : PubMed/NCBI
33	Kusama H, Kikuchi S, Tazawa S, Katsuno K, Baba Y, Zhai YL, Nikaido T and Fujii S: Tranilast inhibits the proliferation of human coronary smooth muscle cell through the activation of p21waf1. Atherosclerosis. 143:307–313. 1999. View Article : Google Scholar : PubMed/NCBI
34	Fox E, Levin K, Zhu Y, Segers B, Balamuth N, Womer R, Bagatell R and Balis F: Pantoprazole, an inhibitor of the organic cation transporter 2, does not ameliorate cisplatin-related ototoxicity or nephrotoxicity in children and adolescents with newly diagnosed osteosarcoma treated with methotrexate, doxorubicin, and cisplatin. Oncologist. 23:762–e779. 2018. View Article : Google Scholar : PubMed/NCBI